Revelation Biosciences announces development plan, partnership initiatives
Revelation Biosciences (REVB) announced plans to accelerate development of its therapeutic candidate Gemini, including a Phase 2a clinical study for acute kidney injury, with data expected in late 2027. The company is also pursuing partnerships and licensing opportunities to support Gemini's development and commercialization.

